The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.
Liver, Gallbladder, and Biliary Tract Cancers
Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib.
A new combination may help with overall and progression-free survival in liver cancer.
Intraoperative bile spillage might serve as a prognostic tool for gall bladder cancer.
Researchers recently reported on the association between upregulation of EPS8L3 and liver cancer prognosis.
Therapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.
Previous laboratory research along with phase I and II trials suggested the combination of doxorubicin and sorafenib could offer improved outcomes in advanced hepatocellular cancer.
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.
Researchers assessed patients with biliary tract cancer (BTC) who underwent ctDNA testing by means of a clinically available assay and analyzed samples using a 73-gene panel.